Clinical Trials Logo

Ocular Hypertension clinical trials

View clinical trials related to Ocular Hypertension.

Filter by:

NCT ID: NCT02246764 Completed - Glaucoma Clinical Trials

Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Start date: September 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the ocular and systemic safety of Netarsudil (AR-13324) Ophthalmic Solution, 0.02% q.d. and b.i.d. for 12 months compared to the active comparator Timolol Maleate Ophthalmic Solution, 0.5%.

NCT ID: NCT02207621 Completed - Ocular Hypertension Clinical Trials

Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension

Start date: July 2014
Phase: Phase 3
Study type: Interventional

Evaluation of the ocular hypotensive efficacy and safety of Netarsudil (AR-13324) Ophthalmic Solution compared to Timolol Maleate Ophthalmic Solution

NCT ID: NCT02207491 Completed - Ocular Hypertension Clinical Trials

Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Rocket-1
Start date: July 2014
Phase: Phase 3
Study type: Interventional

To evaluate the ocular hypotensive efficacy and ocular and systemic safety of AR-13324 Ophthalmic Solution, 0.02% compared to the active comparator Timolol maleate Ophthalmic Solution, 0.5%

NCT ID: NCT02179008 Completed - Ocular Hypertension Clinical Trials

Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

SEE-1
Start date: June 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the safety and efficacy of five concentrations of DE-117 ophthalmic solution.

NCT ID: NCT02167035 Completed - Glaucoma Clinical Trials

Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID)

Start date: August 2014
Phase: Phase 4
Study type: Interventional

To compare Combigan Two Times Daily (BID) vs Simbrinza Three Times Daily (TID) in subjects currently being treated with Latanoprost for Open-Angle Glaucoma or Ocular Hypertension. Both of these drugs are currently FDA approved as combination therapy for patients with Open-Angle Glaucoma or Ocular Hypertension. The purpose of this clinical trial would be to assess which treatment, if either, is superior in lowering intraocular pressure (IOP). A secondary objective is to assess the tolerability of each drug.

NCT ID: NCT02165631 Completed - Ocular Hypertension Clinical Trials

The Diurnal and Nocturnal Effect of Simbrinza and Timolol on Intraocular Pressure and Ocular Perfusion Pressure

Start date: August 2014
Phase: N/A
Study type: Observational

The purpose of this research study is to hypothesize that Simbrinza will achieve a decrease in intraocular pressure and increase in ocular perfusion pressure throughout the diurnal and nocturnal periods. The primary aim of this study will be to determine the effects of Simbrinza at multiple intervals throughout a 24-hour period. The secondary aim will be to compare these to those of timolol.

NCT ID: NCT02143843 Completed - Ocular Hypertension Clinical Trials

An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product

Start date: June 5, 2014
Phase: Phase 2
Study type: Interventional

This study evaluates the long-term (13-months) safety of the Bimatoprost Ocular Insert in participants with Glaucoma or Ocular Hypertension who completed study FSV5-002. All participants received Bimatoprost Ocular Insert and wore it for approximately 7 months, then had the Insert removed and a new insert placed for another 6 months.

NCT ID: NCT02140060 Completed - Glaucoma Clinical Trials

6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Start date: June 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate Travoprost/Brinzolamide fixed combination (Trav/Brinz) administered twice daily as compared to each of its marketed components (TRAVATAN Z® solution and AZOPT® suspension) and to the unfixed combination of TRAVATAN Z® plus AZOPT® in lowering intraocular pressure (IOP).

NCT ID: NCT02136940 Completed - Glaucoma Clinical Trials

Multiple Dose-parallel-group Study of AMA0076 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

Start date: April 2014
Phase: Phase 2
Study type: Interventional

The objective of this parallel group study is to evaluate the safety, tolerability and efficacy of AMA0076 in reduction of intraocular pressure in subjects with primary open-angle glaucoma or ocular hypertension.

NCT ID: NCT02129673 Completed - Ocular Hypertension Clinical Trials

A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Start date: May 2014
Phase: Phase 1/Phase 2
Study type: Interventional

Slow release formulation of latanoprost is compared for safety and pressure-lowering efficacy with topically administration of commercially available latanoprost in patient with glaucoma and ocular hypertension